Renaissance Technologies’s Galectin Therapeutics GALT Stock Holding History

Renaissance Technologies’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$201K	Sell	43,343 -104,557	-71%	-$271K	﹤0.01%	2881
2026 Q1	$413K	Buy	+147,900	New	+$450K	﹤0.01%	2679
2022 Q3	–	Sell	-27,700	Closed	-$36K	–	4151
2022 Q2	$36K	Sell	27,700 -174,318	-86%	-$251K	﹤0.01%	4050
2022 Q1	$325K	Sell	202,018 -13,382	-6%	-$25.9K	﹤0.01%	3435
2021 Q4	$446K	Buy	215,400 +205,304	+2,034%	+$586K	﹤0.01%	3129
2021 Q3	$39K	Sell	10,096 -360,103	-97%	-$1.22M	﹤0.01%	3388
2021 Q2	$1.19M	Buy	370,199 +63,199	+21%	+$225K	﹤0.01%	2581
2021 Q1	$666K	Buy	307,000 +291,373	+1,865%	+$653K	﹤0.01%	2794
2020 Q4	$35K	Buy	+15,627	New	+$41K	﹤0.01%	3331
2020 Q2	–	Sell	-20,100	Closed	-$39K	–	3558
2020 Q1	$39K	Sell	20,100 -19,000	-49%	-$46.2K	﹤0.01%	3343
2019 Q4	$112K	Buy	+39,100	New	+$136K	﹤0.01%	3301
2019 Q3	–	Sell	-34,732	Closed	-$144K	–	3511
2019 Q2	$144K	Buy	+34,732	New	+$150K	﹤0.01%	3354
2018 Q3	–	Sell	-37,300	Closed	-$237K	–	3402
2018 Q2	$237K	Buy	+37,300	New	+$182K	﹤0.01%	3038

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Renaissance Technologies's GALT Position: Q2 2026 in Review

Renaissance Technologies reduced its Galectin Therapeutics (GALT) stake by 71% in Q2 2026, selling an estimated $271K and leaving 43,343 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #2881.

Renaissance Technologies first reported a position in GALT in Q2 2018 and has held it in 13 quarters since. The position peaked at $1.19M in Q2 2021. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

Renaissance Technologies held 43,343 shares of Galectin Therapeutics worth $201K as of Q2 2026.
Renaissance Technologies sold 104,557 Galectin Therapeutics shares in Q2 2026, an estimated $271K.
Galectin Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2881 holding.
Renaissance Technologies first reported a position in Galectin Therapeutics in Q2 2018 and has held it in 13 quarters since.
Renaissance Technologies's Galectin Therapeutics position peaked at $1.19M in Q2 2021.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.